Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Postbiotics

Beneficial Bacterial Metabolites & Components

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

8 human trials, about 80 studies, ~2,000 participants. The written rationale for this grade is still being prepared.

FDA
Varies; some food/supplement
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

This is a young, broad category, and specific health claims often outpace the evidence, especially where a product borrows the postbiotic label without matching human trials. Standardization of dose, characterization, and quantification varies between products, so two postbiotics are not interchangeable. Because inactivation methods differ (heat, high pressure, sonication), a benefit shown for one preparation does not transfer to another. Anyone who is pregnant or breastfeeding, is immunocompromised, is choosing products for infants or children, or is managing metabolic disease should treat product claims cautiously and decide with a qualified healthcare provider rather than from marketing copy. Nothing here is a protocol or a substitute for individualized medical advice.

Postbiotics are defined by the ISAPP 2021 consensus (Salminen et al.) as a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host. The defining feature is that no live organism is required: deliberately inactivated (often heat-killed or tyndallized) whole cells and cell-wall fragments, with or without the metabolites left in the preparation, carry the effect. The category's clearest human evidence sits with specific strains, such as heat-killed Lactobacillus paracasei CBA L74 in children and pasteurized Akkermansia muciniphila in metabolic syndrome, rather than with the label as a whole. Importantly, the ISAPP definition explicitly excludes purified single metabolites, so isolated compounds like butyrate and urolithin A are adjacent to, not examples of, postbiotics as defined. The shelf-stability and safety rationale is appealing, but standardization and regulation are still immature.

The benefit without the live bacteria. Butyrate, urolithin A, equol, heat-killed cells.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Immune modulation via inactivated whole cells and cell-wall fragments (heat-killed L. paracasei strains, EpiCor yeast fermentate, per manufacturer and trial reports)
  • Prevention of common childhood infections in specific fermented-milk products (heat-killed L. paracasei CBA L74, per pediatric RCTs)
  • Metabolic-marker support as a research signal (pasteurized Akkermansia muciniphila, proof-of-concept only)
  • A shelf-stable, viability-free format that avoids the cold-chain and live-count problems of probiotics, an appealing rationale distinct from any single proven clinical endpoint
  • A potentially lower-risk option than live organisms in fragile or immunocompromised contexts, to be decided only with a qualified provider

What people get wrong

  • Often saidPostbiotics are just dead probiotics with no benefit.

    ActuallySpecific heat-killed preparations retain measurable activity: cell-wall components signal through host immune receptors, and in Depommier 2019 pasteurized Akkermansia muciniphila performed as well as or better than the live organism on metabolic markers. The benefit is preparation-specific, not automatic for any killed cell.

  • Often saidButyrate and urolithin A are the star postbiotics.

    ActuallyBoth are important gut-derived molecules, but the ISAPP 2021 definition explicitly excludes purified single metabolites from the term postbiotic. Isolated butyrate or urolithin A (Amazentis Mitopure) is best described as a microbial metabolite, adjacent to postbiotics rather than a definitional example.

  • Often saidThe postbiotic definition is settled science.

    ActuallyThe ISAPP 2021 definition is a consensus, not a universal agreement. Aguilar-Toala and colleagues argued in Nature Reviews Gastroenterology and Hepatology that the term was already defined and that the new definition added confusion; the Salminen group replied in support. Reasonable experts still differ on scope.

  • Often saidPostbiotics are regulated like a distinct product class.

    ActuallyAs of 2025 no major authority (US FDA, EFSA, or Codex) has a dedicated postbiotic framework. Ingredients advance case by case through existing food or supplement pathways, and standardized quantification methods are still being worked out.

Who profits, and who pushes back

  • Jose E. Aguilar-Toala and co-authors

    Pushes backFood-science researchers; published critique of the ISAPP definition in Nature Reviews Gastroenterology and Hepatology (2021)

    Argued that the term postbiotic was already adequately defined and that the ISAPP consensus definition added confusion rather than clarity to the field, particularly in excluding purified metabolites that had previously been treated as postbiotics.

  • Category-standardization researchers (postbiotic quantification perspective, Frontiers in Nutrition 2025)

    Pushes backAnalytical and regulatory reviewers

    Note that a key obstacle to the category is the absence of standardized methods for producing, characterizing, and quantifying postbiotic preparations, which makes cross-product comparison and dose claims unreliable and holds back both regulation and confident clinical claims.

  • Amazentis / Timeline Nutrition

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itUrolithin A brand

    Commercializes urolithin A (Mitopure) with genuine mitophagy and muscle trials; direct commercial interest in the postbiotic narrative.

  • Postbiotic researchers

    Promotes itAcademic

    Growing interest in inanimate, stable alternatives to live probiotics.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
Europe32%
USA30%
Asia24%
Other14%

Research published from: Global.

How we got here

Humans consumed inactivated microbes long before the word existed, through heated and shelf-stored ferments across East Asian, South Asian, and African food traditions, where boiling or drying killed cells that were eaten anyway. Nineteenth-century Irish physicist John Tyndall lent his name to tyndallization, the repeated-heating method still echoed in today's heat-killed preparations. Russian-born Elie Metchnikoff popularized the idea that gut microbes shape health more than a century ago. Japanese researchers then built decades of work on heat-killed lactic-acid bacteria for immune and skin applications. The modern vocabulary is recent: Taverniti and Guglielmetti coined paraprobiotics in 2011 for non-viable cells, and in 2021 an ISAPP panel of 14 experts published a consensus postbiotic definition in Nature Reviews Gastroenterology and Hepatology to end inconsistent usage. That definition was immediately debated, with Aguilar-Toala and colleagues arguing it added confusion, and the Salminen group replying in defense.

  1. 1800sTyndall develops tyndallization, repeated heating that kills microbial cells, a precursor logic to heat-killed preparations
  2. 1900sMetchnikoff popularizes the gut-microbe-and-health idea that later frames inactivated-microbe work
  3. 1990s-2010sJapanese groups build sustained research on heat-killed lactic-acid bacteria for immune and skin uses
  4. 2011Taverniti and Guglielmetti coin paraprobiotics for non-viable microbial cells
  5. 2015Multicenter pediatric RCT: heat-killed L. paracasei CBA L74 fermented milk lowers gastroenteritis and respiratory-infection rates in children
  6. 2019Depommier proof-of-concept: pasteurized Akkermansia muciniphila is safe and improves metabolic markers vs placebo, matching or exceeding live
  7. 2021ISAPP publishes the consensus postbiotic definition; Aguilar-Toala et al. contest it and Salminen et al. reply the same year
  8. 2023-2025Regulators still lack a dedicated postbiotic framework; individual ingredients advance case by case

At a glance

Defined
ISAPP 2021
Includes
SCFAs, cell wall, killed cells
Star metabolite
Urolithin A (mitophagy)
Advantage
No viability requirement

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Postbiotics. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources